As a pioneer of harnessing artificial intelligence (AI) to drug discovery, Insilico Medicine Inc. recently made breakaway progress to bring a generative AI-designed drug to life, announcing the progression of its INS018-055 candidate to phase II trials for idiopathic pulmonary fibrosis.